Biden administration guidance prioritizes race in administering COVID drugs
New York and Minnesota among states prioritizing race in COVID treatment distribution
Guidance issued by the Biden administration states certain individuals may be considered "high risk" and more quickly qualify for monoclonal antibodies and oral antivirals used to treat COVID-19 based on their "race or ethnicity."
In a fact sheet issued for healthcare providers by the Food and Drug Administration, the federal agency approved emergency use authorizations of sotrovimab – a monoclonal antibody proven to be effective against the Omicron variant – only to patients considered "high risk."
The guidance, updated in December 2021, says "medical conditions or factors" such as "race or ethnicity" have the potential to "place individual patients at high risk for progression to severe COVID-19," adding that the "authorization of sotrovimab under the EUA is not limited to" other factors outlined by the agency.
NEW YORK SAYS IT WILL PRIORITIZE NON-WHITE PEOPLE IN DISTRIBUTING LOW SUPPLY OF COVID-19 TREATMENTS
Older age, obesity, pregnancy, chronic kidney disease, diabetes, and cardiovascular disease are among the multiple medical conditions and factors associated with what are considered "high risk" individuals by the FDA.